The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum is a translational science meeting focusing on scientific discoveries made in multiple sclerosis (MS) to advance the understanding of research and clinical care of patients with MS. Every third year, it meets collectively with its European counterpart, ECTRIMS.
Phase 4 CLADRINA Data Supports Transition From Natalizumab to Cladribine in Multiple Sclerosis
March 3rd 2025After 24 months after switching to cladribine, 100% of patients with relapsing MS remained free from T1 gadolinium-enhancing lesions, with no reported cases of PML or rebound disease activity.
A Patient’s Perspective on Progress and Challenges in NMOSD Treatment Advances: Sumaira Ahmed
March 3rd 2025The founder and executive director of the Sumaira Foundation talked about how the landscape of NMOSD treatment has drastically improved with FDA-approved therapies, while noting that accessibility and awareness remain significant challenges. [WATCH TIME: 4 minutes]
Recognizing and Investigating the Prodromal Phase in MS and NMOSD: Dalia Rotstein, MD, MPH
March 2nd 2025The assistant professor of medicine at the University of Toronto talked about emerging research on how prodromal symptoms may aid in the early identification of multiple sclerosis and neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]
Investigating Immune Cell Signatures in Multiple Sclerosis Progression: Stephanie Zandee, PhD
March 1st 2025At the 2025 ACTRIMS Forum, the assistant professor of neuroimmunology at McGill University talked about examining immune cell signatures to track disease worsening in multiple sclerosis. [WATCH TIME: 4 minutes]
Paving the Way for Autoimmune Neurology Treatment With CAR T-Cell Therapy: Amanda Piquet, MD, FAAN
February 28th 2025The autoimmune neurology program director at the University of Colorado talked about the emerging use of CAR T-cell therapy, a breakthrough from oncology, now being explored in autoimmune neurologic diseases like multiple sclerosis. [WATCH TIME: 3 minutes]
Unraveling Smoldering Multiple Sclerosis and Progressive Disability: Bruce Bebo, PhD
February 27th 2025The executive vice president of research at National MS Society discussed the role of compartmentalized inflammation, microglial interactions, and emerging therapeutic targets in multiple sclerosis. [WATCH TIME: 4 minutes]
Phase 4 Study to Test Switch From Anti-CD20 Therapy to Ozanimod in Stable MS
February 27th 2025The study will track patients over 36 months and use T2 lesion count and the number of serious infections as primary endpoints, with secondary endpoints including adverse events, relapse rates, and the achievement of no evidence of disease activity.
Notable Sessions to Eye Amid the 2025 ACTRIMS Forum: Véronique Miron, PhD
February 25th 2025The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave clinical insights on emerging, innovative tracks at the 2025 ACTRIMS Forum and how these sessions align with recent trends in the multiple sclerosis field. [WATCH TIME: 4 minutes]
NeuroVoices: Véronique Miron, PhD, on Exciting Developments and Expectations for ACTRIMS 2025
February 12th 2025The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave an overview for the upcoming ACTRIMS Forum, highlighting key sessions, themes, and advances in the multiple sclerosis field.
Revised McDonald Diagnostic Criteria Signals New Era in Multiple Sclerosis Treatment
October 22nd 2024The 2024 revisions to the McDonald diagnostic criteria for multiple sclerosis (MS) mark a significant advancement in the early detection and diagnosis of the disease, with new biomarkers and a broadened scope that may lead to earlier intervention and improved patient outcomes.
Targeting Neurodegeneration to Impart Neuroprotection in Progressive MS: Shiv Saidha, MBBCh
April 4th 2024The professor of neurology at Johns Hopkins Medicine discussed the limited impact of current therapies on retinal atrophy rates in progressive multiple sclerosis at the 2024 ACTRIMS Forum. [WATCH TIME: 5 minutes]
Analyzing Cognitive Profiles in Multiple Sclerosis and Alzheimer Disease: Le Hua, MD
March 27th 2024The director of the Multiple Sclerosis Program at the Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed findings from a study that compared cognitive profiles between patients with multiple sclerosis and Alzheimer disease. [WATCH TIME: 5 minutes]
Targeting the NLRX1 Pathway for Neuroprotection in Multiple Sclerosis: Marjan Gharagozloo, PhD
March 25th 2024The assistant professor of neurology at Johns Hopkins Medicine talked about recent research that suggests activating the NLRX1 pathway could offer neuroprotection in multiple sclerosis. [WATCH TIME: 5 minutes]
Therapeutic Avenues for Multiple Sclerosis Through Immune Cell Communication: Jeffrey Huang, PhD
March 24th 2024The associate professor of biology at Georgetown University talked about how immune cells can communicate with brain cells to enhance repair processes, which may offer potential treatment targets for multiple sclerosis. [WATCH TIME: 5 minutes]
Clinical Significance of Visual System Modeling for Multiple Sclerosis Research: Shiv Saidha, MBBCh
March 21st 2024The professor of neurology at Johns Hopkins Medicine talked about modeling visual systems as an area of focus in clinical trials for multiple sclerosis as it may offer insights into neurodegeneration and neuroprotection. [WATCH TIME: 6 minutes]